Chiron Completes Sale of $300 Million in Newly Issued Commmon Stock to Novartis.
Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information, please visit www.chiron.com.
This news release contains forward-looking statements that involve risks and uncertainties and are subject to change. In particular, there can be no guarantee that the transaction contemplated by the merger agreement will be consummated. A discussion of the company's operations and financial condition, including factors that may affect its business and future prospects that could cause actual results and developments to differ materially from those expressed or implied by any forward-looking statements, is contained in documents the company has filed with the SEC, including the Form 10-K for the year ended December 31, 2004, and the Form 10-Q for the quarter ended September 30, 2005, and will be contained in all subsequent periodic filings made with the SEC. These documents identify important factors that could cause the company's actual performance to differ from current expectations.
Chiron does not undertake an obligation to update the forward-looking information the company is giving today.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 8, 2005|
|Previous Article:||Cascade Corporation Announces Earnings of $0.84 Per Share for the Quarter Ended October 31, 2005.|
|Next Article:||CPSC, CEC Entertainment Announce Recall of Plastic Siren Whistles.|